Reason for request
The actual benefit of these proprietary products is substantial.
Clinical Added Value
|no clinical added value||
The comparative data for nasal fentanyl versus oral transmucosal fentanyl did not demonstrate superiority of INSTANYL relative to the comparator sharing the same indication ; INSTANYL does not bring an improvement in actual benefit (IAB V) in comparison with therapid-acting opioids indicated in the management of breakthrough pain episodes in adult patients using opioids to treat chronic cancer-related pain.